Literature DB >> 6831429

Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity.

D W Kufe, P P Major, D Munroe, M Egan, D Herrick.   

Abstract

We have used cesium sulfate density gradient centrifugation to monitor the incorporation of 9-beta-D-arabinofuranosyladenine (ara-A) into L1210 cellular nucleic acids. The results demonstrate the specific incorporation of ara-A in L1210 DNA. We have also found a highly significant relationship between the formation of ara-A incorporated into DNA and loss of clonogenic survival. This relationship was maintained when using ara-A in the presence of the adenosine deaminase inhibitor deoxycoformycin. Furthermore, treatment with increasing concentrations of ara-A resulted in a greater proportion of ara-A residues at the 3'-terminus, consistent with this agent providing a poor primer terminus for elongating DNA strands. These findings are similar to those obtained previously with 1-beta-D-arabinofuranosylcytosine and suggest that the incorporation of arabinofuranosyl derivatives in DNA is one mechanism responsible for cell lethality.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831429

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Differential response of human and rodent cell lines to chemical inhibition of the repair of potentially lethal damage.

Authors:  J B Little; A M Ueno; W K Dahlberg
Journal:  Radiat Environ Biophys       Date:  1989       Impact factor: 1.925

2.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Arabinofuranosyl nucleosides induce common fragile sites.

Authors:  J C Leonard; R C Leonard; K H Thompson
Journal:  Hum Genet       Date:  1988-06       Impact factor: 4.132

4.  Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.

Authors:  U Bogdahn; J Zapf; H Weber; G Dünisch; H G Löbering; R Martin; H G Mertens
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.